Clinical Trial Update: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tucidinostat with a PD-1 inhibitor and bevacizumab in advanced esophageal and gastric cancers; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of Esophagogastric Junction
• Esophageal Squamous Cell Carcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 inhibitor
• Tucidinostat (tucidinostat)

Snippet

Sponsor: Ruihua Xu | Conditions: Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN